Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine
dc.contributor.author | Wyatt, Christina M. | |
dc.contributor.author | Kitch, Douglas | |
dc.contributor.author | Gupta, Samir K. | |
dc.contributor.author | Tierney, Camlin | |
dc.contributor.author | Daar, Eric S. | |
dc.contributor.author | Sax, Paul E. | |
dc.contributor.author | Ha, Belinda | |
dc.contributor.author | Melbourne, Kathleen | |
dc.contributor.author | McComsey, Grace A. | |
dc.contributor.author | AIDS Clinical Trials Group Study A5224s Team | |
dc.contributor.department | Department of Medicine, IU School of Medicine | en_US |
dc.date.accessioned | 2016-03-31T16:08:39Z | |
dc.date.available | 2016-03-31T16:08:39Z | |
dc.date.issued | 2014-09-01 | |
dc.description.abstract | BACKGROUND: Antiretroviral therapy (ART) is associated with improved kidney function; however, the nucleotide reverse transcriptase inhibitor (NRTI) tenofovir disoproxil fumarate (TDF) has been associated with decreased kidney function and proteinuria. METHODS: We examined changes in urine protein:creatinine (UPCR) and urine albumin:creatinine (UACR) ratios in 245 ART-naive participants in A5202 randomized in a substudy to blinded NRTI (abacavir/lamivudine, ABC/3TC, n = 124 or TDF/emtricitabine, TDF/FTC, n = 121) with open-label protease inhibitor (PI) atazanavir/ritonavir or nonnucleoside reverse transcriptase inhibitor (NNRTI) efavirenz. RESULTS: At baseline, 18% of participants had clinically significant proteinuria (UPCR ≥200 mg/g), and 11% had clinically significant albuminuria (UACR ≥30 mg/g). The prevalence of clinically significant proteinuria and albuminuria decreased from baseline to week 96 in all treatment groups. In intention-to-treat analyses, there was a significant effect of NRTI component on fold change in UPCR (P = 0.011) and UACR (P = 0.018) from baseline to week 96, with greater improvements in participants randomized to ABC/3TC. There was no significant effect of NNRTI/PI component on fold change in UPCR (P = 0.23) or UACR (P = 0.88), and no significant interactions between NRTI and NNRTI/PI components. CONCLUSIONS: In this prespecified secondary analysis, ART initiation was associated with improvements in proteinuria and albuminuria, with significantly greater improvements in participants randomized to ABC/3TC versus TDF/FTC. These are the first data from a randomized trial to suggest that initiation of TDF/FTC may not be associated with the same degree of improvement in proteinuria and albuminuria that have been reported with other regimens. Future studies should consider the long-term clinical significance of these findings. | en_US |
dc.eprint.version | Author's manuscript | en_US |
dc.identifier.citation | Wyatt, C. M., Kitch, D., Gupta, S. K., Tierney, C., Daar, E. S., Sax, P. E., … McComsey, G. A. (2014). Changes in Proteinuria and Albuminuria with Initiation of Antiretroviral Therapy: Data from a Randomized Trial Comparing Tenofovir Disoproxil Fumarate/Emtricitabine versus Abacavir/Lamivudine. Journal of Acquired Immune Deficiency Syndromes (1999), 67(1), 36–44. http://doi.org/10.1097/QAI.0000000000000245 | en_US |
dc.identifier.issn | 1944-7884 | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/9149 | |
dc.language.iso | en_US | en_US |
dc.publisher | Ovid Technologies (Wolters Kluwer) - Lippincott Williams & Wilkins | en_US |
dc.relation.isversionof | 10.1097/QAI.0000000000000245 | en_US |
dc.relation.journal | Journal of Acquired Immune Deficiency Syndromes (1999) | en_US |
dc.rights | Publisher Policy | en_US |
dc.source | PMC | en_US |
dc.subject | Albuminuria | en_US |
dc.subject | virology | en_US |
dc.subject | Anti-HIV Agents | en_US |
dc.subject | administration & dosage | en_US |
dc.subject | HIV Infections | en_US |
dc.subject | drug therapy | en_US |
dc.subject | Urine | en_US |
dc.subject | HIV-1 | en_US |
dc.subject | drug effects | en_US |
dc.subject | Proteinuria | en_US |
dc.title | Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine | en_US |
dc.type | Article | en_US |